The Heparin Calcium Market is estimated to be valued at US$ 1,370.9 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Heparin calcium is an anticoagulant injection primarily used in cardiovascular surgeries and procedures to prevent blood clots. It acts as an antithrombotic agent and has variety of medical uses in therapy and prophylaxis of thromboembolic disorders.
Market Dynamics:
Increased spending on healthcare sector and growing prevalence of cardiovascular diseases are the major factors driving the growth of the global heparin calcium market. As per the World Health Organization (WHO), cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Furthermore, rising geriatric population base that is more prone to chronic diseases such as CVDs, and new product launches by key players are further fueling the demand for heparin calcium worldwide. However, shortages of raw materials and stringent regulations for approval of heparin calcium are some of the factors expected to hamper the market growth over the forecast period.
Market key trends:
The heparin calcium market is witnessing high demand for low-molecular-weight heparin calcium due to its minimal side effects compared to unfractionated heparin calcium. Low molecular weight heparin calcium has minimal risk of heparin-induced thrombocytopenia (HIT) and bleeding. It also has predictable pharmacokinetics allowing fixed-dose regimens without laboratory monitoring. With growing chronic disease prevalence, the demand for low bleeding risks anticoagulants is increasing rapidly.
SWOT Analysis
Strength: Heparin calcium is widely used as an anticoagulant in surgical procedures and for treating clotting disorders. It has high efficacy and a well established safety profile.
Weakness: Fragility against heat and moisture makes transport and storage challenging. Risk of bleeding and heparin-induced thrombocytopenia (HIT) are major limitations.
Opportunity: Increasing usage of low molecular weight heparin calcium provides major opportunities due to its lower bleeding risk. Growing geriatric population prone to chronic diseases is driving the overall market.
Threats: Entry of generic versions and alternative novel oral anticoagulants poses pricing pressure on established heparin calcium products. Stringent regulatory approvals also restrict entry of new players.
Key Takeaways
The Global Heparin Calcium Market size was valued at USD 1,370.9 Mn in 2023 and is expected to expand at a CAGR of 2.7% during 2022-2030. Increasing prevalence of cardiovascular, thrombosis and orthopedic diseases is a key factor fueling market revenue. Additionally, rising geriatric population and growing number of surgical procedures also contributes significantly to market growth. North America dominated the market in 2022 owing to presence of major players and rise in product approvals. Asia Pacific is likely to emerge as the fastest growing market over the forecast period due to expansion of healthcare infrastructure and increasing generic drugs approvals in countries like China and India. Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd. and Aspen Holdings. These companies focus on product innovation and new launches to strengthen their market position.
The Heparin Calcium Market is estimated to be valued at US$ 1,370.9 Mn in 2023 and is expected to exhibit a CAGR of 2.7% over the forecast period 2022 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Heparin calcium is an anticoagulant injection primarily used in cardiovascular surgeries and procedures to prevent blood clots. It acts as an antithrombotic agent and has variety of medical uses in therapy and prophylaxis of thromboembolic disorders.
Market Dynamics:
Increased spending on healthcare sector and growing prevalence of cardiovascular diseases are the major factors driving the growth of the global heparin calcium market. As per the World Health Organization (WHO), cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Furthermore, rising geriatric population base that is more prone to chronic diseases such as CVDs, and new product launches by key players are further fueling the demand for heparin calcium worldwide. However, shortages of raw materials and stringent regulations for approval of heparin calcium are some of the factors expected to hamper the market growth over the forecast period.
Market key trends:
The heparin calcium market is witnessing high demand for low-molecular-weight heparin calcium due to its minimal side effects compared to unfractionated heparin calcium. Low molecular weight heparin calcium has minimal risk of heparin-induced thrombocytopenia (HIT) and bleeding. It also has predictable pharmacokinetics allowing fixed-dose regimens without laboratory monitoring. With growing chronic disease prevalence, the demand for low bleeding risks anticoagulants is increasing rapidly.
SWOT Analysis
Strength: Heparin calcium is widely used as an anticoagulant in surgical procedures and for treating clotting disorders. It has high efficacy and a well established safety profile.
Weakness: Fragility against heat and moisture makes transport and storage challenging. Risk of bleeding and heparin-induced thrombocytopenia (HIT) are major limitations.
Opportunity: Increasing usage of low molecular weight heparin calcium provides major opportunities due to its lower bleeding risk. Growing geriatric population prone to chronic diseases is driving the overall market.
Threats: Entry of generic versions and alternative novel oral anticoagulants poses pricing pressure on established heparin calcium products. Stringent regulatory approvals also restrict entry of new players.
Key Takeaways
The Global Heparin Calcium Market size was valued at USD 1,370.9 Mn in 2023 and is expected to expand at a CAGR of 2.7% during 2022-2030. Increasing prevalence of cardiovascular, thrombosis and orthopedic diseases is a key factor fueling market revenue. Additionally, rising geriatric population and growing number of surgical procedures also contributes significantly to market growth. North America dominated the market in 2022 owing to presence of major players and rise in product approvals. Asia Pacific is likely to emerge as the fastest growing market over the forecast period due to expansion of healthcare infrastructure and increasing generic drugs approvals in countries like China and India. Key players operating in the heparin calcium market are Sanofi, Pfizer Inc., Dongying Tiandong Pharmaceutical Co., Ltd., PANPHARMA S.A., Merck KGaA, Teva Pharmaceutical Industries Ltd., SMITHFIELD BIOSCIENCE, Afine Chemicals Limited, Yino Pharma Limited, Shandong Sheelian Pharmaceutical Co., Ltd. and Aspen Holdings. These companies focus on product innovation and new launches to strengthen their market position.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
